Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Yves Cahn

Showing results (51-60 of 168) with videos related to

Pageof 17
Sort By:
Leukemia|November 16, 2019
The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantationArnon Nagler, Bhagirathbhai Dholaria, Myriam Labopin, et al.
Blood|October 7, 2011
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemiaBob Löwenberg, Petra Muus, Gert Ossenkoppele, et al.
The Lancet. Oncology|July 11, 2014
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trialsRobert K Hills, Sylvie Castaigne, Frederick R Appelbaum, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 17, 2018
Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationThomas Heinicke, Myriam Labopin, Christoph Schmid, et al.
Oncotarget|January 20, 2018
Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMTGabrielle Roth-Guepin, Jonathan Canaani, Annalisa Ruggeri, et al.
British Journal of Haematology|December 8, 2010
Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)Marie Robin, Reza Tabrizi, Mohamad Mohty, et al.
Bone Marrow Transplantation|January 14, 2018
Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow TransplantationRaynier Devillier, Myriam Labopin, Patrice Chevallier, et al.
British Journal of Haematology|August 16, 2002
The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phaseEduardo Olavarria, Josy Reiffers, Concha Boque, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroupThomas Prébet, Nicolas Boissel, Sarah Reutenauer, et al.
British Journal of Haematology|May 11, 2012
Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFMShanti Natarajan-Amé, Sophie Park, Lionel Ades, et al.
Pageof 17

Showing results (51-60 of 168) with videos related to

Sort By:
Pageof 17
Leukemia|November 16, 2019
The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantationArnon Nagler, Bhagirathbhai Dholaria, Myriam Labopin, et al.
Blood|October 7, 2011
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemiaBob Löwenberg, Petra Muus, Gert Ossenkoppele, et al.
The Lancet. Oncology|July 11, 2014
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trialsRobert K Hills, Sylvie Castaigne, Frederick R Appelbaum, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 17, 2018
Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationThomas Heinicke, Myriam Labopin, Christoph Schmid, et al.
Oncotarget|January 20, 2018
Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMTGabrielle Roth-Guepin, Jonathan Canaani, Annalisa Ruggeri, et al.
British Journal of Haematology|December 8, 2010
Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)Marie Robin, Reza Tabrizi, Mohamad Mohty, et al.
Bone Marrow Transplantation|January 14, 2018
Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow TransplantationRaynier Devillier, Myriam Labopin, Patrice Chevallier, et al.
British Journal of Haematology|August 16, 2002
The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phaseEduardo Olavarria, Josy Reiffers, Concha Boque, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroupThomas Prébet, Nicolas Boissel, Sarah Reutenauer, et al.
British Journal of Haematology|May 11, 2012
Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFMShanti Natarajan-Amé, Sophie Park, Lionel Ades, et al.
Pageof 17